-- 加拿大皇家银行(RBC)在周二公布数据后表示,油价飙升和黄金出口再次大幅增长是推动加拿大3月份贸易收支重回顺差的主要因素。 该行指出,除上述产品外,其他数据喜忧参半,但总体上与外部需求仍受美国关税影响,但仍呈现企稳迹象的总体趋势相符。 剔除价格因素,第一季度整体出口仍同比下降2.4%——其中,(高额关税的)钢铁和木材产品出口分别比去年同期下降50%和22%。但汽车出口已从年初的生产中断中持续复苏。 剔除价格因素后,整体出口量自2025年3月以来首次略高于去年同期水平。 加拿大皇家银行(RBC)指出,第一季度进口激增导致净贸易额与第一季度GDP增速相差4个百分点,但这与相对强劲的国内需求相符,其中包括工业设备和进口17%的年化增长率——这对加拿大企业投资而言是一个积极的信号。 尽管未来几个月美墨加协定(CUSMA)续签谈判可能加剧,贸易仍存在显著的不确定性,但该行仍然预计,在基本假设下,2026年美国关税环境将更加稳定——尽管部分产品的关税税率仍将显著较高——这将使贸易对经济增长的阻力小于2025年。 该行补充道,中东冲突推高了加拿大和国际家庭的生活成本,但油价上涨带来的能源净出口激增也显著增加了流入产油区的收入。 加拿大皇家银行对经济的基本展望预计,加之加拿大央行此前降息措施的滞后影响以及政府支出计划的增加,未来一年人均和人均经济状况将进一步改善。
Related Articles
American Electric Power CEO Says Speed to Market Key Issue in Load Connection
American Electric Power (AEP) CEO Bill Fehrman said Tuesday that speed to market is the main issue in efficiently connecting energy load to generation.In a Q1 earnings call, Fehrman said that, in particular, the performance and stakeholder approval process of PJM, the US mid-Atlantic grid operator, represents a major challenge."The current state of PJM's performance and stakeholder approval process does not give me great confidence that these issues will be resolved any time soon," Fehrman said on the call."In fact, if something is not done now, I expect we could still be having these same conversations in 10 years," he added.Expanding and strengthening the grid will ensure new generation resources can connect quickly, reliably, and affordably to serve the growing load, the CEO said.Price: $137.27, Change: $+2.61, Percent Change: +1.94%
MGE Energy Q1 Earnings, Revenue Rise
MGE Energy (MGEE) reported Q1 earnings Tuesday of $1.32 per diluted share, up from $1.14 a year earlier.One analyst polled by FactSet expected $1.13.Revenue for the three months ended March 31 was $242.7 million, up from $219 million a year earlier.Price: $80.48, Change: $+0.36, Percent Change: +0.46%
Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $28 from $31, 9.4x our 2027 EPS estimate, below PFE's historical forward P/E average. We keep our 2026 EPS view at $2.99 and our 2027 EPS at $2.97. PFE delivered solid top- and bottom-line Q1 results today that exceeded expectations while demonstrating continued progress in its post-Covid transition strategy. While we continue to think that shares are trading at a discount, as the company's main focus in the next year is on AI integration, and a new transformative M&A is not a key priority, we see limited catalysts to drive meaningful upside potential. We think PFE is aiming to maximize value from launched and acquired products with particular focus on key areas: oncology, obesity/metabolic disease, and vaccines. PFE remains committed to maintaining its dividend, continuing productivity initiatives ($7.2B cost savings target), and pursuing targeted business development (with $7B capacity) but we do not expect PFE executing share buybacks to support the share price in the near term.